<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152655</url>
  </required_header>
  <id_info>
    <org_study_id>2019-278</org_study_id>
    <nct_id>NCT04152655</nct_id>
  </id_info>
  <brief_title>A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease</brief_title>
  <acronym>SEASEiPPD</acronym>
  <official_title>A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Nanjing Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Hangzhou Normal University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether 24 months of idebenone may reduce the progression from Prodromal&#xD;
      Parkinson disease (PPD) to Parkinson disease (PD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Number of people suffered from Parkinson disease (PD) is increasing every year. Contemporary&#xD;
      medication has little neuroprotective effect, which may due to delayed treatment as over 50%&#xD;
      neurons have lost when clinical diagnosed PD emerges. The concept of Prodromal Parkinson&#xD;
      disease (PPD) is emphasized as it has become evident that there are several risk and clinical&#xD;
      markers may occur years before the cardinal motor symptoms which allow clinical diagnosis.&#xD;
      Rapid eye movement (REM) sleep behavior disorder and olfactory dysfunction are the most&#xD;
      common PPD, and more than one third of patients may progress to PD and other&#xD;
      neurodegenerative diseases. Mitochondrial injury is one of the pathogenesis of PD. Thus we&#xD;
      design this trial to investigate whether idebenone, potent coenzyme Q10 analogue, could&#xD;
      protect PPD develops into PD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical diagnosis of parkinson disease</measure>
    <time_frame>24 months</time_frame>
    <description>based on Movement Disorder Society (MDS) Research Criteria for Prodromal Parkinson's Disease in 2015</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dopamine transporter positron emission tomography (DAT-PET) change</measure>
    <time_frame>12 month and 24 month</time_frame>
    <description>diminishment of striatal DAT-PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative motor testing change</measure>
    <time_frame>24 months</time_frame>
    <description>Unified Parkinson Disease Rating Scale, Part III</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>REM Sleep Behavior Disorder</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Group 1: idebenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral 30 mg fixed dose three times a day x 24-months (90 mg total / day) with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo three times a day x 24-months with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>30mg tablets three times a day</description>
    <arm_group_label>Group 1: idebenone</arm_group_label>
    <other_name>Coenzyme Q10 analogue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>placebo tablets three times a day</description>
    <arm_group_label>Group 2: placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects are voluntary to participate and have signed informed consent&#xD;
&#xD;
          -  Diagnosed as Rapid Eye movement (REM) Sleep Behavior Disorder by polysomnography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects are pregnant, breastfeeding, or want to get pregnant or breastfeeding in 2&#xD;
             years&#xD;
&#xD;
          -  Subjects have history of allergy to idebenone&#xD;
&#xD;
          -  Difficulty to communicate&#xD;
&#xD;
          -  Suffering from neurodegenerative diseases&#xD;
&#xD;
          -  Having obvious brain imaging abnormalities (eg. severe brain atrophy, malformation,&#xD;
             softening lesions, cerebrovascular disease, intracranial occupancy, giant large benign&#xD;
             lesions, etc.)&#xD;
&#xD;
          -  Having severe mental illness (eg. schizophrenia, manic depression, and severe&#xD;
             depression)&#xD;
&#xD;
          -  Long-term use of clonidine, dopamine antagonists, and serotonin reuptake inhibitors&#xD;
&#xD;
          -  Suffering from other severe medical conditions&#xD;
&#xD;
          -  Having difficulty in moving and are unable to come to the hospital&#xD;
&#xD;
          -  Having claustrophobia&#xD;
&#xD;
          -  Having contraindications to MRI tests&#xD;
&#xD;
          -  Having history of olfactory disorders greater than 10 years&#xD;
&#xD;
          -  Having history of color vision disorders greater than 10 years&#xD;
&#xD;
          -  Life expectancy less than 2 years&#xD;
&#xD;
          -  Having other situations which researchers consider is inappropriate to participate in&#xD;
             this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baorong Zhang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital of Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baorong Zhang, MD</last_name>
    <phone>+86 13958167260</phone>
    <email>brzhang@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baorong Zhang, MD</last_name>
      <phone>+86 13958167260</phone>
      <email>brzhang@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Baorong Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Idebenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

